Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMASPECT: Lampalizumab extension in GA
NCT02745119Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2016
- Primary completion
- Jan 2018
- Modality
- Antibody Fragments
- Countries
- 19
01
Overview
Phase 3, open-label trial of lampalizumab in geographic atrophy (GA) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Ocular Adverse Events at 1 year, Percentage of Participants With Systemic (Non-Ocular) Adverse Events at 1 year and 1 more. Started Jul 2016; status: terminated.
02
Drugs
lampalizumab
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02745119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745119.